Machine Learning–Based Prediction of Distant Recurrence Risk and Ribociclib Treatment Effect in HR+/HER2− Early Breast Cancer Using Real-World and NATALEE Data
A machine learning model was developed that accurately predicted distant recurrence in HR+/HER2- EBC. The identified predictor variables and developed models may aid in risk-based personalized treatment decision-making.
Authors
- Peter A. Fasching (ORCID: https://orcid.org/0000-0003-4885-8471)
- Murat Akdere (ORCID: https://orcid.org/0009-0001-4883-0463)
- Christine Brezden‐Masley (ORCID: https://orcid.org/0000-0002-4818-318X)
- Pedram Razavi (ORCID: https://orcid.org/0000-0003-4236-0576)
- Frederick M. Howard (ORCID: https://orcid.org/0000-0002-6039-1141)
- Cesar A. Santa‐Maria (ORCID: https://orcid.org/0000-0003-0979-8787)
- Oleg B. Blyuss (ORCID: https://orcid.org/0000-0002-0194-6389)
- Thomas Bachelot (ORCID: https://orcid.org/0000-0002-0866-9484)
- Patricia Domínguez Castro (ORCID: https://orcid.org/0000-0002-2871-9573)
- Christoph Kurz (ORCID: https://orcid.org/0000-0001-9498-8002)
- F. Ye (ORCID: https://orcid.org/0009-0003-4211-3062)
- Joseph A. Sparano (ORCID: https://orcid.org/0000-0002-9031-2010)
- Maryam B. Lustberg (ORCID: https://orcid.org/0000-0001-8559-5645)
- Elgene Lim (ORCID: https://orcid.org/0000-0001-8065-8838)
- Yeon Hee Park (ORCID: https://orcid.org/0000-0003-4156-9212)
- Kristyn Pantoja (ORCID: https://orcid.org/0000-0003-2745-1808)
Institutions
- Novartis (Switzerland) (CH)
- Mount Sinai Hospital (CA)
- Memorial Sloan Kettering Cancer Center (US)
- Garvan Institute of Medical Research (AU)
- Johns Hopkins University (US)
- Queen Mary University of London (GB)
- Samsung Medical Center (KR)
- Yale University (US)
- Kettering University (US)
- University of Chicago (US)
- Novartis (Germany) (DE)
- Universitätsklinikum Erlangen (DE)
- Centre Léon Bérard (FR)
- Novartis (United States) (US)
- St Vincent's Clinic (AU)
- Tisch Hospital (US)
- Comprehensive Cancer Center Erlangen (DE)
- Novartis (Ireland) (IE)
- Tris Pharma (United States) (US)
- Sidney Kimmel Comprehensive Cancer Center (US)
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2025-11-10
- DOI
- https://doi.org/10.1158/1078-0432.ccr-25-1946
- Citations
- 2
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 3.04
Funders
- Amgen
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Sanofi
- Gilead Sciences
- Astex Pharmaceuticals
- BeiGene
- Veracyte
- Seagen
- Invitae
- Astellas Pharma
- Novartis Institutes for BioMedical Research
- Daiichi Sankyo Europe